Page last updated: 2024-11-07

cariporide

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

cariporide: a selective sodium-hydrogen exchange subtype 1 inhibitor; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID151172
CHEMBL ID436559
SCHEMBL ID39639
MeSH IDM0246278

Synonyms (47)

Synonym
AC-14535
159138-80-4
hoe-642
4-isopropyl-3-(methylsulfonyl)benzoyl-guanidine methanesulfonate
n-(diaminomethylene)-4-isopropyl-3-(methylsulfonyl)benzamide
benzamide, n-(aminoiminomethyl)-4-(1-methylethyl)-3-(methylsulfonyl)-
cariporide
n-(aminoiminomethyl)-4-(1-methylethyl)-3-(methylsulfonyl)benzamide
cariporide [inn]
hoe642
CHEMBL436559 ,
n-(diaminomethylidene)-3-methylsulfonyl-4-propan-2-ylbenzamide
n-(4-isopropyl-3-methanesulfonyl-benzoyl)-guanidine (cariporide)
n-(4-isopropyl-3-methanesulfonyl-benzoyl)-guanidine
n-(4-isopropyl-3-methanesulfonyl-benzoyl)-guanidine(cariporide)
bdbm50058759
NCGC00247951-01
7e3392891k ,
unii-7e3392891k
FT-0602930
AKOS015854493
benzamide, n-(diaminomethylene)-4-(1-methylethyl)-3-(methylsulfonyl)-
cariporide [mi]
cariporide [who-dd]
S5814
SCHEMBL39639
IWXNYAIICFKCTM-UHFFFAOYSA-N
3-methylsulfonyl-4-i-propylbenzoylguanidine
n-(diaminomethylidene)-3-(methylsulfonyl)-4-(propan-2-yl)benzamide
DTXSID8047345
AKOS025142097
AC-31727
EX-A886
n-carbamimidoyl-3-methanesulfonyl-4-(propan-2-yl)benzamide
mfcd00864683
n-[bis(azanyl)methylidene]-3-methylsulfonyl-4-propan-2-yl-benzamide
cariporide, >=98% (hplc)
J-009566
HY-19693
CS-6968
4-isopropyl-3-methylsulphonylbenzoyl-guanidine
Q5039665
DB06468
DS-11823
159138-73-5
BCP15215
bdbm50234609

Research Excerpts

Overview

Cariporide is a sodium/hydrogen ion exchange inhibitor under development by Aventis Pharma, formerly Hoechst Marion Roussel (HMR) It is a potential treatment for myocardial infarction (MI), ischemic damage due to angioplasty and reperfusion following thrombolysis.

ExcerptReferenceRelevance
"Cariporide is an orally active inhibitor of NHE-1 (6000 ppm in rat chow)."( The role of the sodium hydrogen exchanger-1 in mediating diabetes-induced changes in the retina.
Chakrabarti, S; Cukiernik, M; Downey, D; Evans, T; Hileeto, D; Karmazyn, M; Khan, ZA,
)
0.85
"Cariporide (HOE 642) is a recently synthesized NHE-1 inhibitor."( Blocking Na(+)-H+ exchange by cariporide reduces Na(+)-overload in ischemia and is cardioprotective.
Decking, UK; Hartmann, M, 1999
)
1.31
"Cariporide is a sodium/hydrogen ion exchange inhibitor under development by Aventis Pharma, formerly Hoechst Marion Roussel (HMR), as a potential treatment for myocardial infarction (MI), ischemic damage due to angioplasty and reperfusion following thrombolysis. "( Cariporide Aventis.
Chin, B; Lip, GY, 2000
)
3.19
"Cariporide (HOE642) is a recently developed inhibitor of the myocardial sodium-hydrogen exchange system. "( Lessons learned from a phase III population pharmacokinetic study of cariporide in coronary artery bypass graft surgery.
Harnisch, L; Jessel, A; Weber, W, 2002
)
1.99

Effects

ExcerptReferenceRelevance
"Cariporide has recently been evaluated in a large dose-finding Phase II/Phase III clinical trial (GUARDIAN) to assess its efficacy in patients with acute coronary syndromes."( Pharmacology and clinical assessment of cariporide for the treatment coronary artery diseases.
Karmazyn, M, 2000
)
1.3

Actions

Cariporide can suppress the apoptosis of cardiac muscle cells in rats. S3226 did not inhibit the formation of the blastocoel cavity from the morula stage.

ExcerptReferenceRelevance
"Cariporide can suppress the apoptosis of cardiac muscle cells in rats (within 30 min) after death caused by warm ischemia."( [Effect of cariporide on the expression of bcl-2 and bax genes after neck heart transplantation from non heart-beating rats caused by warm ischemia].
Chen, SX; Luo, FY; Wang, L, 2008
)
1.46
"Cariporide did not inhibit the formation of the blastocoel cavity from the morula stage whereas S3226 did inhibit that process."( Na+ / H+ exchanger-3 is involved in mouse blastocyst formation.
Kawagishi, R; Morishige, K; Murata, Y; Sakata, M; Sawada, K; Tahara, M; Tasaka, K, 2004
)
1.04

Treatment

Cariporide treatment did not alter MG-triggered upregulation of P- and E-selectins, but reduced endothelial ICAM-1 expression. Cariporides decreased the TUNEL-positive cells, the Bax-to-Bcl-2 ratio (3.16 +/- 0.32 vs. 3.16), and the pHi and VEGF secretion.

ExcerptReferenceRelevance
"In cariporide-treated group, dialysate myoglobin concentrations were significantly lower than those in vehicle group throughout ischemia/reperfusion (P<0.01 at 0-15 min of ischemia, P<0.05 at 15-30 min of ischemia, P<0.01 at 0-15 min of reperfusion, and P<0.01 at 15-30 min of reperfusion)."( Effects of intravenous cariporide on release of norepinephrine and myoglobin during myocardial ischemia/reperfusion in rabbits.
Akiyama, T; Kawada, T; Kuroko, Y; Sakurai, S; Sano, S; Shimizu, S; Sugimachi, M; Yamazaki, T, 2014
)
1.23
"Cariporide treatment did not alter MG-triggered upregulation of P- and E-selectins, but reduced endothelial ICAM-1 expression."( Endothelial Na+/H+ exchanger NHE1 participates in redox-sensitive leukocyte recruitment triggered by methylglyoxal.
Cayabyab, FS; Liu, L; Qadri, SM; Su, Y, 2014
)
1.12
"Cariporide treatment decreased the TUNEL-positive cells, the Bax-to-Bcl-2 ratio (3.16 +/- 0.32 vs."( Chronic NHE-1 blockade induces an antiapoptotic effect in the hypertrophied heart.
Caldiz, CI; Chiappe de Cingolani, GE; Ennis, IL; Garciarena, CD; Portiansky, EL, 2009
)
1.07
"Cariporide treatment of K562 resulted in a decrease in pHi and down-regulation of VEGF secretion."( Inhibition of K562 leukemia angiogenesis and growth by selective Na+/H+ exchanger inhibitor cariporide through down-regulation of pro-angiogenesis factor VEGF.
Chang, G; Gao, W; Jin, W; Li, H; Li, Q; Lin, Y; Ma, L; Pang, T; Wang, J; Wang, L, 2011
)
1.31
"When cariporide pre-treatment was combined with AMP 579 at reperfusion, infarction was further limited (14.2 +/- 4.5%)."( Protection from AMP 579 can be added to that from either cariporide or ischemic preconditioning in ischemic rabbit heart.
Cohen, MV; Downey, JM; Jiao, Z; Xu, Z, 2002
)
1.02
"Cariporide pretreatment caused a similar return of preload recruitable stroke work to 86% +/- 9% and 90% +/- 6% after buffered or nonbuffered cardioplegia (P <.05 vs nonpretreated groups), allowed only minor creatine kinase MB and conjugated diene changes, and reduced endothelin-1 release 3-fold compared with hearts without sodium-hydrogen exchange blockage."( A new role for cardioplegic buffering: should acidosis or calcium accumulation be counteracted to salvage jeopardized hearts?
Buckberg, GD; Castellá, M; Ignarro, LJ; Saleh, S; Tan, Z, 2003
)
1.04
"Cariporide treatment significantly improved postischemic segment shortening, stroke work, preload recruitable stroke work, and preload recruitable stroke work area and had no systemic hemodynamic effects. "( Sodium-hydrogen exchange inhibition attenuates in vivo porcine myocardial stunning.
Lasley, RD; Mentzer, RM; Salik Jahania, M; Stevens, RM, 2004
)
1.77
"Cariporide treatment significantly improved PRSW (64+/-7 mmHg), dp/dt(max) (8077+/-525 mmHg s(-1)) and EDPVR (0.026+/-0.014 mmHg microl(-1)), and reduced cardiac hypertrophy in rats with MI."( Effects of combined inhibition of the Na+-H+ exchanger and angiotensin-converting enzyme in rats with congestive heart failure after myocardial infarction.
Busch, AE; Gehring, D; Gerl, M; Hiss, K; Ruetten, H; Schaefer, S; Schindler, U, 2005
)
1.05
"Cariporide-treated hearts were smaller, slower beating, with greater developed LVP."( Insulin-sensitizing and cardiovascular effects of the sodium-hydrogen exchange inhibitor, cariporide, in the JCR: LA-cp rat and db/db mouse.
Busch, AE; Kelly, SE; Löhn, M; Proctor, SD; Russell, JC; Schäfer, S, 2005
)
1.27
"Cariporide treatment restored relaxation to acetylcholine after hypoxia-reoxygenation in adult rings (-32.04% vs."( Protection of endothelial-derived vasorelaxation with cariporide, a sodium-proton exchanger inhibitor, after prolonged hypoxia and hypoxia-reoxygenation: effect of age.
Besse, S; Boucher, F; de Leiris, J; Huraux, C; Riou, B; Swynghedauw, B; Tanguy, S, 2006
)
1.3
"cariporide- and BIIB723-treated SHR, respectively; p<0.05) and decreased myocardial brain natriuretic peptide, calcineurin Abeta, and nuclear NFAT expressions."( Normalization of the calcineurin pathway underlies the regression of hypertensive hypertrophy induced by Na+/H+ exchanger-1 (NHE-1) inhibition.
Camilión de Hurtado, MC; Cingolani, HE; Dulce, RA; Ennis, IL; Escudero, EM; Garciarena, CD; Pérez, NG,
)
0.85
"Cariporide treatment in group 1 and group 2 significantly improved functional recovery after 24 hours of reperfusion."( Na(+)/H(+) exchange inhibitor cariporide attenuates cell injury predominantly during ischemia and not at onset of reperfusion in porcine hearts with low residual blood flow.
Bohle, RM; Klein, HH; Lindert-Heimberg, S; Nebendahl, K; Pich, S, 2000
)
1.32
"Treatment with cariporide reduced the degree of liver injury, as determined by alanine aminotransferase (ALT) values, also when administered after the induction of hepatic damage."( Selective Na+/H+ exchange inhibition by cariporide reduces liver fibrosis in the rat.
Bendia, E; Benedetti, A; Candelaresi, C; Di Sario, A; Kleemann, HW; Macarri, G; Marzioni, M; Pigini, P; Schindler, U; Taffetani, S; Trozzi, L, 2003
)
0.93
"Pre-treatment with cariporide delayed ATP depletion (luminescence assay in rat myocardium) and onset of rigor contracture (tension recordings or ultrasonic crystals) during ischemia both in rat and pig hearts (P<0.05). "( Pre-treatment with the Na+/H+ exchange inhibitor cariporide delays cell-to-cell electrical uncoupling during myocardial ischemia.
Agulló, L; Barrabés, JA; García-Dorado, D; Inserte, J; Padilla, F; Rodríguez-Sinovas, A; Ruiz-Meana, M; Soler-Soler, J, 2003
)
0.9
"untreated), cariporide (p < 0.01 vs."( Na+ overload during ischemia and reperfusion in rat hearts: comparison of the Na+/H+ exchange blockers EIPA, cariporide and eniporide.
ten Hove, M; van Echteld, CJ; van Emous, JG, 2003
)
0.89
"Pretreatment with cariporide in the setting of ischemia-reperfusion injury provides greater protection against the development of diastolic abnormalities than probucol when Celsior solution is used for both arrest and preservation. "( Na+/H+ exchange inhibition and antioxidants lack additive protective effects after reperfusion injury in the working heterotopic rat heart isograft.
Curtis, LJ; Rabkin, DG; Spotnitz, HM; Weinberg, AD, 2005
)
0.66
"Treatment with cariporide (0.01, 0.1, 1 micromol/L) of aortic rings incubated with high-glucose medium attenuated the impaired endothelium-dependent relaxation in a dose-dependent manner."( Na+/H+ exchanger inhibitor prevented endothelial dysfunction induced by high glucose.
Li-Ying, L; Shuang-Xi, W; Yu-Hui, L, 2005
)
0.67
"Treatment with cariporide, levosimendan, or their combination both before and after ischaemia, and treatment with cariporide after ischaemia caused a 25% greater recovery of LVdp than in control hearts."( Myocardial stunning following no flow ischaemia is diminished by levosimendan or cariporide, without benefits of combined administration.
Behrends, M; Brendt, P; Peters, J, 2008
)
0.91
"Treatment with cariporide (10 mg kg(-1) i.v.) significantly reduced leukocyte rolling, adhesion and extravasation after thrombin exposure. "( Sodium/hydrogen exchange inhibition with cariporide reduces leukocyte adhesion via P-selectin suppression during inflammation.
Buerke, M; Buerke, U; Carter, JM; Dahm, M; Makowski, J; Niemann, B; Prondzinsky, R; Pruefer, D; Rohrbach, S; Russ, M; Schlitt, A; Schulze, C; Vahl, CF; Werdan, K, 2008
)
0.96
"Treatment with cariporide was commenced either 1 week pre or 30 min, 3 h, 24 h or 7 days after ligation of the left ventricular artery and was continued until haemodynamic parameters were obtained 6 weeks after MI in conscious rats."( Cardioprotective effects of the Na(+)/H(+)-exchange inhibitor cariporide in infarct-induced heart failure.
Chung, O; Daemen, MJ; Illner, S; Jähnichen, G; Reinecke, A; Rossius, B; Sandmann, S; Spitznagel, H; Unger, T; Xia, Q, 2000
)
0.9

Pharmacokinetics

A population pharmacokinetic model of cariporide was developed with use of data from phase I studies.

ExcerptReferenceRelevance
"A population pharmacokinetic model of cariporide was developed with use of data from phase I studies."( Lessons learned from a phase III population pharmacokinetic study of cariporide in coronary artery bypass graft surgery.
Harnisch, L; Jessel, A; Weber, W, 2002
)
0.82
" In this study, we characterized the pharmacodynamic properties of new guanidine NHE1 inhibitors (cariporide, sabiporide, KR-32511, KR-32570, and KR-33028) to analyze their myocardial protective effects."( Pharmacodynamic characteristics and cardioprotective effects of new NHE1 inhibitors.
Han, W; Jung, YS; Kim, J; Kim, KH; Kim, MY; Lee, BH; Lee, MG; Namkung, W; Yi, KY; Yoo, SE, 2007
)
0.56

Bioavailability

ExcerptReferenceRelevance
" In addition, the gem-dimethyl series of analogues seem to display improved oral bioavailability and longer plasma half-life in rats."( Arylcyclopropanecarboxyl guanidines as novel, potent, and selective inhibitors of the sodium hydrogen exchanger isoform-1.
Ahmad, S; Atwal, KS; Chen, AY; Chen, BC; DiMarco, JD; Dorso, CR; Doweyko, LM; Dugar, S; Gavin, BJ; Gougoutas, JZ; Grazier, N; Kirby, M; Lan, SJ; Ngu, K; Serafino, R; Wu, SC; Yost, KJ, 2001
)
0.31

Dosage Studied

ExcerptRelevanceReference
" This suggests that insufficient dosage may have accounted, at least in part, for the less than optimum results."( Pharmacology and clinical assessment of cariporide for the treatment coronary artery diseases.
Karmazyn, M, 2000
)
0.57
"Our objective was to identify an optimal dosing regimen that might offer increased protection during the period of highest risk."( Lessons learned from a phase III population pharmacokinetic study of cariporide in coronary artery bypass graft surgery.
Harnisch, L; Jessel, A; Weber, W, 2002
)
0.55
"A dosing regimen with a loading dose of an infusion of 120 mg/h for 1 hour followed by an infusion of 20 mg/h for 47 hours should achieve stable exposure above the estimated minimal effective concentration in more than 95% of patients during and after coronary artery bypass graft surgery."( Lessons learned from a phase III population pharmacokinetic study of cariporide in coronary artery bypass graft surgery.
Harnisch, L; Jessel, A; Weber, W, 2002
)
0.55
" The dose-response curves elicited by ACh from HCHF diet rabbits were more significantly shifted to the right than those from HCHF diet plus HOE 642-treated rabbits."( [Protective effect of Na(+)-H+ exchanger inhibitor cariporide on the injury of vascular endothelial function induced by hypercholesterolemia].
Liu, LY; Tu, JH; Zhang, XH, 2002
)
0.57
"Inhibition of the Na (+)/H (+) exchanger (NHE) is cardioprotective, but dosage and timing of NHE-inhibitors are critical for their efficacy."( The Na+/H+ exchange inhibitor cariporide is washed out of the myocardium by crystalloid cardioplegia.
Bartels, C; Bechtel, JF; Eichler, W; Hernandez, M; Klotz, KF; Sievers, HH; Toerber, K; Weidtmann, B, 2006
)
0.62
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (8)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Sodium/hydrogen exchanger 1Homo sapiens (human)IC50 (µMol)1.08020.00500.56013.5000AID1341120; AID1341847; AID1411094; AID1435501; AID143805; AID143806; AID241110; AID242052; AID270790; AID298722
Sodium/hydrogen exchanger 1Oryctolagus cuniculus (rabbit)IC50 (µMol)0.02600.00800.01760.0260AID167716; AID205451
Sodium/hydrogen exchanger 1Rattus norvegicus (Norway rat)IC50 (µMol)0.05890.01000.64613.9000AID143803; AID295040; AID599650; AID618425
Sodium/hydrogen exchanger 3Oryctolagus cuniculus (rabbit)IC50 (µMol)0.02600.00800.01700.0260AID167716; AID205451
Sodium/hydrogen exchanger 3Homo sapiens (human)IC50 (µMol)8.25000.00050.00350.0050AID1341122; AID1341853; AID1411099; AID143809
Sodium/hydrogen exchanger 2Oryctolagus cuniculus (rabbit)IC50 (µMol)0.02600.00800.26131.0000AID167716; AID205451
Sodium/hydrogen exchanger 5Homo sapiens (human)IC50 (µMol)30.00000.42000.42000.4200AID1341117; AID1341852; AID1411100; AID143810
Sodium/hydrogen exchanger 2Homo sapiens (human)IC50 (µMol)27.60002.00004.01439.2000AID1341121; AID1341850; AID1411095; AID143807; AID143808; AID270791
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (43)

Processvia Protein(s)Taxonomy
monoatomic ion transportSodium/hydrogen exchanger 1Homo sapiens (human)
intracellular sodium ion homeostasisSodium/hydrogen exchanger 1Homo sapiens (human)
regulation of pHSodium/hydrogen exchanger 1Homo sapiens (human)
response to acidic pHSodium/hydrogen exchanger 1Homo sapiens (human)
positive regulation of cardiac muscle hypertrophySodium/hydrogen exchanger 1Homo sapiens (human)
regulation of cardiac muscle contraction by calcium ion signalingSodium/hydrogen exchanger 1Homo sapiens (human)
cell migrationSodium/hydrogen exchanger 1Homo sapiens (human)
maintenance of cell polaritySodium/hydrogen exchanger 1Homo sapiens (human)
positive regulation of cell growthSodium/hydrogen exchanger 1Homo sapiens (human)
cellular response to insulin stimulusSodium/hydrogen exchanger 1Homo sapiens (human)
positive regulation of mitochondrial membrane permeabilitySodium/hydrogen exchanger 1Homo sapiens (human)
response to muscle stretchSodium/hydrogen exchanger 1Homo sapiens (human)
sodium ion export across plasma membraneSodium/hydrogen exchanger 1Homo sapiens (human)
positive regulation of apoptotic processSodium/hydrogen exchanger 1Homo sapiens (human)
negative regulation of apoptotic processSodium/hydrogen exchanger 1Homo sapiens (human)
positive regulation of action potentialSodium/hydrogen exchanger 1Homo sapiens (human)
positive regulation of transcription by RNA polymerase IISodium/hydrogen exchanger 1Homo sapiens (human)
stem cell differentiationSodium/hydrogen exchanger 1Homo sapiens (human)
protein complex oligomerizationSodium/hydrogen exchanger 1Homo sapiens (human)
regulation of intracellular pHSodium/hydrogen exchanger 1Homo sapiens (human)
regulation of stress fiber assemblySodium/hydrogen exchanger 1Homo sapiens (human)
regulation of focal adhesion assemblySodium/hydrogen exchanger 1Homo sapiens (human)
cardiac muscle cell differentiationSodium/hydrogen exchanger 1Homo sapiens (human)
cellular response to coldSodium/hydrogen exchanger 1Homo sapiens (human)
positive regulation of calcineurin-NFAT signaling cascadeSodium/hydrogen exchanger 1Homo sapiens (human)
cellular response to antibioticSodium/hydrogen exchanger 1Homo sapiens (human)
cellular response to electrical stimulusSodium/hydrogen exchanger 1Homo sapiens (human)
cellular response to mechanical stimulusSodium/hydrogen exchanger 1Homo sapiens (human)
cellular response to organic cyclic compoundSodium/hydrogen exchanger 1Homo sapiens (human)
cellular response to hypoxiaSodium/hydrogen exchanger 1Homo sapiens (human)
cellular response to acidic pHSodium/hydrogen exchanger 1Homo sapiens (human)
cellular response to epinephrine stimulusSodium/hydrogen exchanger 1Homo sapiens (human)
cardiac muscle cell contractionSodium/hydrogen exchanger 1Homo sapiens (human)
regulation of cardiac muscle cell membrane potentialSodium/hydrogen exchanger 1Homo sapiens (human)
regulation of the force of heart contraction by cardiac conductionSodium/hydrogen exchanger 1Homo sapiens (human)
sodium ion import across plasma membraneSodium/hydrogen exchanger 1Homo sapiens (human)
positive regulation of the force of heart contractionSodium/hydrogen exchanger 1Homo sapiens (human)
proton transmembrane transportSodium/hydrogen exchanger 1Homo sapiens (human)
positive regulation of calcium:sodium antiporter activitySodium/hydrogen exchanger 1Homo sapiens (human)
potassium ion transmembrane transportSodium/hydrogen exchanger 1Homo sapiens (human)
monoatomic ion transportSodium/hydrogen exchanger 3Homo sapiens (human)
regulation of intracellular pHSodium/hydrogen exchanger 3Homo sapiens (human)
sodium ion import across plasma membraneSodium/hydrogen exchanger 3Homo sapiens (human)
proton transmembrane transportSodium/hydrogen exchanger 3Homo sapiens (human)
potassium ion transmembrane transportSodium/hydrogen exchanger 3Homo sapiens (human)
monoatomic ion transportSodium/hydrogen exchanger 5Homo sapiens (human)
sodium ion transmembrane transportSodium/hydrogen exchanger 5Homo sapiens (human)
regulation of intracellular pHSodium/hydrogen exchanger 5Homo sapiens (human)
proton transmembrane transportSodium/hydrogen exchanger 5Homo sapiens (human)
potassium ion transmembrane transportSodium/hydrogen exchanger 5Homo sapiens (human)
sodium ion import across plasma membraneSodium/hydrogen exchanger 5Homo sapiens (human)
monoatomic ion transportSodium/hydrogen exchanger 2Homo sapiens (human)
protein localizationSodium/hydrogen exchanger 2Homo sapiens (human)
epithelial cell differentiationSodium/hydrogen exchanger 2Homo sapiens (human)
proton transmembrane transportSodium/hydrogen exchanger 2Homo sapiens (human)
sodium ion import across plasma membraneSodium/hydrogen exchanger 2Homo sapiens (human)
potassium ion transmembrane transportSodium/hydrogen exchanger 2Homo sapiens (human)
regulation of intracellular pHSodium/hydrogen exchanger 2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (15)

Processvia Protein(s)Taxonomy
protein bindingSodium/hydrogen exchanger 1Homo sapiens (human)
calmodulin bindingSodium/hydrogen exchanger 1Homo sapiens (human)
phospholipid bindingSodium/hydrogen exchanger 1Homo sapiens (human)
phosphatidylinositol-4,5-bisphosphate bindingSodium/hydrogen exchanger 1Homo sapiens (human)
sodium:proton antiporter activitySodium/hydrogen exchanger 1Homo sapiens (human)
protein phosphatase 2B bindingSodium/hydrogen exchanger 1Homo sapiens (human)
protein-macromolecule adaptor activitySodium/hydrogen exchanger 1Homo sapiens (human)
identical protein bindingSodium/hydrogen exchanger 1Homo sapiens (human)
calcium-dependent protein bindingSodium/hydrogen exchanger 1Homo sapiens (human)
molecular adaptor activitySodium/hydrogen exchanger 1Homo sapiens (human)
sodium:proton antiporter activity involved in regulation of cardiac muscle cell membrane potentialSodium/hydrogen exchanger 1Homo sapiens (human)
potassium:proton antiporter activitySodium/hydrogen exchanger 1Homo sapiens (human)
protein bindingSodium/hydrogen exchanger 3Homo sapiens (human)
sodium:proton antiporter activitySodium/hydrogen exchanger 3Homo sapiens (human)
PDZ domain bindingSodium/hydrogen exchanger 3Homo sapiens (human)
phosphatidylinositol bindingSodium/hydrogen exchanger 3Homo sapiens (human)
identical protein bindingSodium/hydrogen exchanger 3Homo sapiens (human)
potassium:proton antiporter activitySodium/hydrogen exchanger 3Homo sapiens (human)
protein bindingSodium/hydrogen exchanger 5Homo sapiens (human)
sodium:proton antiporter activitySodium/hydrogen exchanger 5Homo sapiens (human)
arrestin family protein bindingSodium/hydrogen exchanger 5Homo sapiens (human)
potassium:proton antiporter activitySodium/hydrogen exchanger 5Homo sapiens (human)
sodium:proton antiporter activitySodium/hydrogen exchanger 2Homo sapiens (human)
potassium:proton antiporter activitySodium/hydrogen exchanger 2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (25)

Processvia Protein(s)Taxonomy
nucleoplasmSodium/hydrogen exchanger 1Homo sapiens (human)
cytoplasmSodium/hydrogen exchanger 1Homo sapiens (human)
mitochondrionSodium/hydrogen exchanger 1Homo sapiens (human)
plasma membraneSodium/hydrogen exchanger 1Homo sapiens (human)
focal adhesionSodium/hydrogen exchanger 1Homo sapiens (human)
cell surfaceSodium/hydrogen exchanger 1Homo sapiens (human)
intercalated discSodium/hydrogen exchanger 1Homo sapiens (human)
membraneSodium/hydrogen exchanger 1Homo sapiens (human)
basolateral plasma membraneSodium/hydrogen exchanger 1Homo sapiens (human)
apical plasma membraneSodium/hydrogen exchanger 1Homo sapiens (human)
lamellipodiumSodium/hydrogen exchanger 1Homo sapiens (human)
T-tubuleSodium/hydrogen exchanger 1Homo sapiens (human)
membrane raftSodium/hydrogen exchanger 1Homo sapiens (human)
perinuclear region of cytoplasmSodium/hydrogen exchanger 1Homo sapiens (human)
extracellular exosomeSodium/hydrogen exchanger 1Homo sapiens (human)
cation-transporting ATPase complexSodium/hydrogen exchanger 1Homo sapiens (human)
plasma membraneSodium/hydrogen exchanger 1Homo sapiens (human)
early endosomeSodium/hydrogen exchanger 3Homo sapiens (human)
plasma membraneSodium/hydrogen exchanger 3Homo sapiens (human)
brush borderSodium/hydrogen exchanger 3Homo sapiens (human)
cell surfaceSodium/hydrogen exchanger 3Homo sapiens (human)
apical plasma membraneSodium/hydrogen exchanger 3Homo sapiens (human)
brush border membraneSodium/hydrogen exchanger 3Homo sapiens (human)
early endosome membraneSodium/hydrogen exchanger 3Homo sapiens (human)
recycling endosome membraneSodium/hydrogen exchanger 3Homo sapiens (human)
extracellular exosomeSodium/hydrogen exchanger 3Homo sapiens (human)
apical plasma membraneSodium/hydrogen exchanger 3Homo sapiens (human)
plasma membraneSodium/hydrogen exchanger 3Homo sapiens (human)
brush border membraneSodium/hydrogen exchanger 3Homo sapiens (human)
plasma membraneSodium/hydrogen exchanger 5Homo sapiens (human)
focal adhesionSodium/hydrogen exchanger 5Homo sapiens (human)
membraneSodium/hydrogen exchanger 5Homo sapiens (human)
dendritic spine membraneSodium/hydrogen exchanger 5Homo sapiens (human)
neuron spineSodium/hydrogen exchanger 5Homo sapiens (human)
synapseSodium/hydrogen exchanger 5Homo sapiens (human)
postsynaptic membraneSodium/hydrogen exchanger 5Homo sapiens (human)
recycling endosome membraneSodium/hydrogen exchanger 5Homo sapiens (human)
plasma membraneSodium/hydrogen exchanger 5Homo sapiens (human)
plasma membraneSodium/hydrogen exchanger 2Homo sapiens (human)
membraneSodium/hydrogen exchanger 2Homo sapiens (human)
apical plasma membraneSodium/hydrogen exchanger 2Homo sapiens (human)
plasma membraneSodium/hydrogen exchanger 2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (70)

Assay IDTitleYearJournalArticle
AID270790Inhibition of human NHE1 expressed in Ap1 cell line2006Bioorganic & medicinal chemistry letters, Sep-15, Volume: 16, Issue:18
Synthesis and biological activity of 5-aryl-4-(4-(5-methyl-1H-imidazol-4-yl)piperidin-1-yl)pyrimidine analogs as potent, highly selective, and orally bioavailable NHE-1 inhibitors.
AID249241In vitro cardioprotective effect of compound on left ventricular end diastolic pressure (LVEDP) in isolated ischemic rat heart (10 uM); Control = 55 mmHg2005Bioorganic & medicinal chemistry letters, Jun-15, Volume: 15, Issue:12
4-Substituted (benzo[b]thiophene-2-carbonyl)guanidines as novel Na+/H+ exchanger isoform-1 (NHE-1) inhibitors.
AID143806In vitro concentration required to inhibit NHE-1 mediated intracellular maximal pH recovery by 50%2001Bioorganic & medicinal chemistry letters, Mar-26, Volume: 11, Issue:6
Discovery of zoniporide: a potent and selective sodium-hydrogen exchanger type 1 (NHE-1) inhibitor with high aqueous solubility.
AID167716Inhibition of 5-N-(ethyl isopropyl)-amiloride[EIPA]-sensitive Na+ uptake into acidified rabbit erythrocytes.1997Journal of medicinal chemistry, Jun-20, Volume: 40, Issue:13
(2-Methyl-5-(methylsulfonyl)benzoyl)guanidine Na+/H+ antiporter inhibitors.
AID143808In vitro concentration of compound required to inhibit NHE-2 mediated intracellular maximal pH recovery by 50%2001Bioorganic & medicinal chemistry letters, Mar-26, Volume: 11, Issue:6
Discovery of zoniporide: a potent and selective sodium-hydrogen exchanger type 1 (NHE-1) inhibitor with high aqueous solubility.
AID420744Cardioprotective activity in Langendorff-perfused guinea pig heart assessed as inhibition of global ischemia-induced diastolic contracture at 1 uM2009Journal of medicinal chemistry, Jul-23, Volume: 52, Issue:14
Na+ currents in cardioprotection: better to be late.
AID249730In vivo anti-infarction effect was determined by measuring percent ratio of myocardial infarct size to area at risk (IS/AAR)in rat myocardial infarction model upon administration of 1.0 mg/kg 2005Journal of medicinal chemistry, Apr-21, Volume: 48, Issue:8
(5-Arylfuran-2-ylcarbonyl)guanidines as cardioprotectives through the inhibition of Na+/H+ exchanger isoform-1.
AID588211Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in humans2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID599753Cardioprotective activity against ischemia-reperfusion injury in Sprague-Dawley rat assessed as increase in SOD activity in serum at 1 mg/kg, iv2009Bioorganic & medicinal chemistry letters, Jun-15, Volume: 19, Issue:12
Design, synthesis and biological evaluation of novel substituted benzoylguanidine derivatives as potent Na+/H+ exchanger inhibitors.
AID588213Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in non-rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID599750Cardioprotective activity against ischemia-reperfusion injury in Sprague-Dawley rat assessed as decrease in creatine kinase release at 1 mg/kg, iv2009Bioorganic & medicinal chemistry letters, Jun-15, Volume: 19, Issue:12
Design, synthesis and biological evaluation of novel substituted benzoylguanidine derivatives as potent Na+/H+ exchanger inhibitors.
AID143801In vitro inhibition against Na+/H+ exchanger(NHE) by measuring its ability to inhibit the acid induced swelling in human platelets by 50%2002Journal of medicinal chemistry, Jul-04, Volume: 45, Issue:14
Novel, non-acylguanidine-type Na(+)/H(+) exchanger inhibitors: synthesis and pharmacology of 5-tetrahydroquinolinylidene aminoguanidine derivatives.
AID420751Cardioprotective activity in Langendorff perfused Landrace pig assessed decrease in troponin 1 plasma level administered iv 60 mins before ischemia measured after 6 hrs of reperfusion2009Journal of medicinal chemistry, Jul-23, Volume: 52, Issue:14
Na+ currents in cardioprotection: better to be late.
AID245760In vitro cardioprotective effect in isolated ischemic rat heart model as recovery of rate pressure product (RPP) at 3 uM2005Journal of medicinal chemistry, Apr-21, Volume: 48, Issue:8
(5-Arylfuran-2-ylcarbonyl)guanidines as cardioprotectives through the inhibition of Na+/H+ exchanger isoform-1.
AID358118Inhibition of Amphiuma tridactylum wild type NHE1 expressed in chinese hamster AP1 cells assessed as intracellular pHi recovery by ammonium chloride prepulse protocol2007The Journal of biological chemistry, Jul-06, Volume: 282, Issue:27
NHE1 inhibition by amiloride- and benzoylguanidine-type compounds. Inhibitor binding loci deduced from chimeras of NHE1 homologues with endogenous differences in inhibitor sensitivity.
AID143809Compound is screened in AP1 cells expressing human NHE-3 for sodium hydrogen exchange activity2001Journal of medicinal chemistry, Sep-27, Volume: 44, Issue:20
Arylcyclopropanecarboxyl guanidines as novel, potent, and selective inhibitors of the sodium hydrogen exchanger isoform-1.
AID232710Selectivity ratio of NHE-1 verus NHE-2 was determined2001Bioorganic & medicinal chemistry letters, Mar-26, Volume: 11, Issue:6
Discovery of zoniporide: a potent and selective sodium-hydrogen exchanger type 1 (NHE-1) inhibitor with high aqueous solubility.
AID298725Cardioprotective effect against ischemia reperfusion injury in rat myocardial infarction model assessed as ratio of infarction size to area at risk at 0.1 mg/kg, iv2007Bioorganic & medicinal chemistry letters, Mar-01, Volume: 17, Issue:5
3-Substituted-(5-arylfuran-2-ylcarbonyl)guanidines as NHE-1 inhibitors.
AID599759Cardioprotective activity against Langendorff perfused Sprague-Dawley rat heart assessed as increase in myocardial energy metabolism at 10 uM2009Bioorganic & medicinal chemistry letters, Jun-15, Volume: 19, Issue:12
Design, synthesis and biological evaluation of novel substituted benzoylguanidine derivatives as potent Na+/H+ exchanger inhibitors.
AID432230Cardioprotective activity against ischemic Sprague-Dawley rat heart assessed as reduction in infarct size at 1 mg/kg, iv treated 5 mins before left anterior descending coronary artery occlusion measured after 2 hrs of reperfusion by Evans staining2009European journal of medicinal chemistry, Sep, Volume: 44, Issue:9
Synthesis and bioactivity of substituted indan-1-ylideneaminoguanidine derivatives.
AID270792Selectivity for human NHE1 over NHE22006Bioorganic & medicinal chemistry letters, Sep-15, Volume: 16, Issue:18
Synthesis and biological activity of 5-aryl-4-(4-(5-methyl-1H-imidazol-4-yl)piperidin-1-yl)pyrimidine analogs as potent, highly selective, and orally bioavailable NHE-1 inhibitors.
AID93158Concentration to achieve half-maximal inhibition of acid-induced swelling in human platelets using platelet swelling assay1998Journal of medicinal chemistry, Sep-10, Volume: 41, Issue:19
Bicyclic acylguanidine Na+/H+ antiporter inhibitors.
AID432234Cardioprotective activity against ischemic Sprague-Dawley rat heart assessed as serum creatine kinase level at 1 mg/kg, iv treated 5 mins before left anterior descending coronary artery occlusion measured after 2 hrs of reperfusion by Evans staining2009European journal of medicinal chemistry, Sep, Volume: 44, Issue:9
Synthesis and bioactivity of substituted indan-1-ylideneaminoguanidine derivatives.
AID205451Sodium/hydrogen exchanger antiport activity was measured using [22]Na+ uptake inhibition assay in acidified rabbit erythrocytes1998Journal of medicinal chemistry, Sep-10, Volume: 41, Issue:19
Bicyclic acylguanidine Na+/H+ antiporter inhibitors.
AID701662Oral bioavailability in jugular and femoral vein precannulated Sprague-Dawley rat plasma at 5 mg/kg by LC/MS/MS analysis2012Journal of medicinal chemistry, Aug-23, Volume: 55, Issue:16
Identification of a potent sodium hydrogen exchanger isoform 1 (NHE1) inhibitor with a suitable profile for chronic dosing and demonstrated cardioprotective effects in a preclinical model of myocardial infarction in the rat.
AID249726In vivo anti-infarction effect by ratio of myocardial infarct size to area at risk in rat myocardial infarction model upon administration of 0.3 mg/kg 2005Journal of medicinal chemistry, Apr-21, Volume: 48, Issue:8
(5-Arylfuran-2-ylcarbonyl)guanidines as cardioprotectives through the inhibition of Na+/H+ exchanger isoform-1.
AID358313Inhibition of Pleuronectes americanus NHE1 TM4 mutant containing TFFLF sequence of Amphiuma tridactylum expressed in chinese hamster AP1 cells assessed as intracellular pHi recovery by ammonium chloride prepulse protocol2007The Journal of biological chemistry, Jul-06, Volume: 282, Issue:27
NHE1 inhibition by amiloride- and benzoylguanidine-type compounds. Inhibitor binding loci deduced from chimeras of NHE1 homologues with endogenous differences in inhibitor sensitivity.
AID599751Cardioprotective activity against ischemia-reperfusion injury in Sprague-Dawley rat assessed as decrease in LDH release at 1 mg/kg, iv2009Bioorganic & medicinal chemistry letters, Jun-15, Volume: 19, Issue:12
Design, synthesis and biological evaluation of novel substituted benzoylguanidine derivatives as potent Na+/H+ exchanger inhibitors.
AID143803In vitro inhibition of acid induced swelling in rat platelets by 50% as a measure of NHE-1 inhibition2002Journal of medicinal chemistry, Jul-04, Volume: 45, Issue:14
Novel, non-acylguanidine-type Na(+)/H(+) exchanger inhibitors: synthesis and pharmacology of 5-tetrahydroquinolinylidene aminoguanidine derivatives.
AID225641In vivo inhibitory effect on the myocardial infarct size of ischemia-reperfusion injury model of rat administered intravenously 5 min before occlusion2002Journal of medicinal chemistry, Jul-04, Volume: 45, Issue:14
Novel, non-acylguanidine-type Na(+)/H(+) exchanger inhibitors: synthesis and pharmacology of 5-tetrahydroquinolinylidene aminoguanidine derivatives.
AID358120Inhibition of Pleuronectes americanus NHE1 C-terminal mutant containing TM7 domain of Amphiuma tridactylum expressed in chinese hamster AP1 cells assessed as intracellular pHi recovery by ammonium chloride prepulse protocol2007The Journal of biological chemistry, Jul-06, Volume: 282, Issue:27
NHE1 inhibition by amiloride- and benzoylguanidine-type compounds. Inhibitor binding loci deduced from chimeras of NHE1 homologues with endogenous differences in inhibitor sensitivity.
AID701665Clearance in jugular and femoral vein precannulated Sprague-Dawley rat at 1 mg/kg, iv by LC/MS/MS analysis relative to hepatic blood flow2012Journal of medicinal chemistry, Aug-23, Volume: 55, Issue:16
Identification of a potent sodium hydrogen exchanger isoform 1 (NHE1) inhibitor with a suitable profile for chronic dosing and demonstrated cardioprotective effects in a preclinical model of myocardial infarction in the rat.
AID599752Cardioprotective activity against ischemia-reperfusion injury in Sprague-Dawley rat assessed as decrease in malondialdehyde at 1 mg/kg, iv2009Bioorganic & medicinal chemistry letters, Jun-15, Volume: 19, Issue:12
Design, synthesis and biological evaluation of novel substituted benzoylguanidine derivatives as potent Na+/H+ exchanger inhibitors.
AID241110Inhibitory activity against Na+/H+ exchanger 1 (NHE-1) expressed in PS120 cells2005Journal of medicinal chemistry, Apr-21, Volume: 48, Issue:8
(5-Arylfuran-2-ylcarbonyl)guanidines as cardioprotectives through the inhibition of Na+/H+ exchanger isoform-1.
AID420749Cardioprotective activity in Langendorff perfused Landrace pig heart assessed decrease in myocardial infarct volume administered iv 60 mins before ischemia followed by 30 mins of reperfusion2009Journal of medicinal chemistry, Jul-23, Volume: 52, Issue:14
Na+ currents in cardioprotection: better to be late.
AID588212Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID599650Inhibition of NHE1-mediated rat platelet swelling2009Bioorganic & medicinal chemistry letters, Jun-15, Volume: 19, Issue:12
Design, synthesis and biological evaluation of novel substituted benzoylguanidine derivatives as potent Na+/H+ exchanger inhibitors.
AID249728In vivo anti-infarction effect was determined by measuring percent ratio of myocardial infarct size to area at risk (IS/AAR)in rat myocardial infarction model upon administration of 0.1 mg/kg 2005Journal of medicinal chemistry, Apr-21, Volume: 48, Issue:8
(5-Arylfuran-2-ylcarbonyl)guanidines as cardioprotectives through the inhibition of Na+/H+ exchanger isoform-1.
AID599760Cardioprotective activity against Langendorff perfused Sprague-Dawley rat heart assessed as increase in relaxing coronary artery at 10 uM2009Bioorganic & medicinal chemistry letters, Jun-15, Volume: 19, Issue:12
Design, synthesis and biological evaluation of novel substituted benzoylguanidine derivatives as potent Na+/H+ exchanger inhibitors.
AID599749Cardioprotective activity against ischemia-reperfusion injury in Sprague-Dawley rat assessed as decrease in myocardial infarct size at 1 mg/kg, iv2009Bioorganic & medicinal chemistry letters, Jun-15, Volume: 19, Issue:12
Design, synthesis and biological evaluation of novel substituted benzoylguanidine derivatives as potent Na+/H+ exchanger inhibitors.
AID420743Cardioprotective activity in Wistar rat atrium assessed as inhibition of veratridine-induced diastolic contracture at 1 uM administered 15 mins before veratridine challenge2009Journal of medicinal chemistry, Jul-23, Volume: 52, Issue:14
Na+ currents in cardioprotection: better to be late.
AID270791Inhibition of human NHE2 expressed in Ap1 cell line2006Bioorganic & medicinal chemistry letters, Sep-15, Volume: 16, Issue:18
Synthesis and biological activity of 5-aryl-4-(4-(5-methyl-1H-imidazol-4-yl)piperidin-1-yl)pyrimidine analogs as potent, highly selective, and orally bioavailable NHE-1 inhibitors.
AID245761In vitro cardioprotective effect in isolated ischemic rat heart model as recovery of rate pressure product (RPP) at 10 uM2005Journal of medicinal chemistry, Apr-21, Volume: 48, Issue:8
(5-Arylfuran-2-ylcarbonyl)guanidines as cardioprotectives through the inhibition of Na+/H+ exchanger isoform-1.
AID420748Cardioprotective activity against myocardial ischemia-reperfusion in Landrace pig heart assessed as prevention of post reperfusion injury after 48 hrs2009Journal of medicinal chemistry, Jul-23, Volume: 52, Issue:14
Na+ currents in cardioprotection: better to be late.
AID358311Inhibition of Amphiuma tridactylum NHE1 mutant containing TM10-12 domain of Pleuronectes americanus expressed in chinese hamster AP1 cells assessed as intracellular pHi recovery by ammonium chloride prepulse protocol2007The Journal of biological chemistry, Jul-06, Volume: 282, Issue:27
NHE1 inhibition by amiloride- and benzoylguanidine-type compounds. Inhibitor binding loci deduced from chimeras of NHE1 homologues with endogenous differences in inhibitor sensitivity.
AID245759In vitro cardioprotective effect in isolated ischemic rat heart model as recovery of rate pressure product (RPP) at 1 uM2005Journal of medicinal chemistry, Apr-21, Volume: 48, Issue:8
(5-Arylfuran-2-ylcarbonyl)guanidines as cardioprotectives through the inhibition of Na+/H+ exchanger isoform-1.
AID242052Inhibitory concentration against human sodium/hydrogen exchanger (NHE-1) in PS120 variant cells2005Bioorganic & medicinal chemistry letters, Jun-15, Volume: 15, Issue:12
4-Substituted (benzo[b]thiophene-2-carbonyl)guanidines as novel Na+/H+ exchanger isoform-1 (NHE-1) inhibitors.
AID618425Inhibition of NHE1 in Sprague-Dawley rat assessed as inhibition of acid-induced platelet swelling by spectrophotometric analysis2011European journal of medicinal chemistry, Sep, Volume: 46, Issue:9
Synthesis and Na+/H+ exchanger inhibitory activity of benzoylguanidine derivatives.
AID358312Inhibition of Pleuronectes americanus NHE1 TM4 mutant containing VFFLF sequence of human expressed in chinese hamster AP1 cells assessed as intracellular pHi recovery by ammonium chloride prepulse protocol2007The Journal of biological chemistry, Jul-06, Volume: 282, Issue:27
NHE1 inhibition by amiloride- and benzoylguanidine-type compounds. Inhibitor binding loci deduced from chimeras of NHE1 homologues with endogenous differences in inhibitor sensitivity.
AID249471In vivo cardioprotective effect measured as ratio of myocardial infarction size to area at risk (IS/AAR) in rat myocardial infarction model at 0.1 mg/kg; control = 59%2005Bioorganic & medicinal chemistry letters, Jun-15, Volume: 15, Issue:12
4-Substituted (benzo[b]thiophene-2-carbonyl)guanidines as novel Na+/H+ exchanger isoform-1 (NHE-1) inhibitors.
AID358314Inhibition of Pleuronectes americanus NHE1 C-terminal mutant with replacement of residues C-terminal to 489 position with corresponding residues of Amphiuma tridactylum expressed in chinese hamster AP1 cells assessed as intracellular pHi recovery by ammon2007The Journal of biological chemistry, Jul-06, Volume: 282, Issue:27
NHE1 inhibition by amiloride- and benzoylguanidine-type compounds. Inhibitor binding loci deduced from chimeras of NHE1 homologues with endogenous differences in inhibitor sensitivity.
AID358310Inhibition of Pleuronectes americanus NHE1 mutant containing TM10-12 domain of Amphiuma tridactylum expressed in chinese hamster AP1 cells assessed as intracellular pHi recovery by ammonium chloride prepulse protocol2007The Journal of biological chemistry, Jul-06, Volume: 282, Issue:27
NHE1 inhibition by amiloride- and benzoylguanidine-type compounds. Inhibitor binding loci deduced from chimeras of NHE1 homologues with endogenous differences in inhibitor sensitivity.
AID358117Inhibition of Pleuronectes americanus wild type NHE1 expressed in chinese hamster AP1 cells assessed as intracellular pHi recovery by ammonium chloride prepulse protocol2007The Journal of biological chemistry, Jul-06, Volume: 282, Issue:27
NHE1 inhibition by amiloride- and benzoylguanidine-type compounds. Inhibitor binding loci deduced from chimeras of NHE1 homologues with endogenous differences in inhibitor sensitivity.
AID143807Compound is screened in AP1 cells expressing human NHE-2 for sodium hydrogen exchange activity2001Journal of medicinal chemistry, Sep-27, Volume: 44, Issue:20
Arylcyclopropanecarboxyl guanidines as novel, potent, and selective inhibitors of the sodium hydrogen exchanger isoform-1.
AID143805Screened in AP1 cells expressing human NHE-1 for sodium hydrogen exchange activity2001Journal of medicinal chemistry, Sep-27, Volume: 44, Issue:20
Arylcyclopropanecarboxyl guanidines as novel, potent, and selective inhibitors of the sodium hydrogen exchanger isoform-1.
AID1435501Inhibition of platelet NHE1 in human platelet rich plasma assessed as decrease in platelet swelling preincubated for 3 mins followed by sodium propionate addition measured after 4 mins by spectrophotometric method2017European journal of medicinal chemistry, Jan-27, Volume: 126Sodium hydrogen exchanger inhibitory activity of benzotriazole derivatives.
AID295039Cardioprotective effect aganist myocardial ischemic-reperfusion injury in Sprague-Dawley rat assessed as infract size at 0.01 mmol/kg, iv administered 5 mins before LAD occlusion2007Bioorganic & medicinal chemistry letters, May-01, Volume: 17, Issue:9
Benzimidazol-2-yl or benzimidazol-2-ylthiomethyl benzoylguanidines as novel Na+/H+ exchanger inhibitors, synthesis and protection against ischemic-reperfusion injury.
AID432233Inhibition of NHE1 in Sprague-Dawley rat platelet-rich plasma by optical swelling assay2009European journal of medicinal chemistry, Sep, Volume: 44, Issue:9
Synthesis and bioactivity of substituted indan-1-ylideneaminoguanidine derivatives.
AID358121Inhibition of Pleuronectes americanus NHE1 C-terminal mutant containing TM10 domain of Amphiuma tridactylum expressed in chinese hamster AP1 cells assessed as intracellular pHi recovery by ammonium chloride prepulse protocol2007The Journal of biological chemistry, Jul-06, Volume: 282, Issue:27
NHE1 inhibition by amiloride- and benzoylguanidine-type compounds. Inhibitor binding loci deduced from chimeras of NHE1 homologues with endogenous differences in inhibitor sensitivity.
AID251004Effect of compound on lactate dehydrogenase (LDH) release into the effluent perfusate during reperfusion of isolated ischemic rat heart (10 uM); Control = 28 IU/g2005Bioorganic & medicinal chemistry letters, Jun-15, Volume: 15, Issue:12
4-Substituted (benzo[b]thiophene-2-carbonyl)guanidines as novel Na+/H+ exchanger isoform-1 (NHE-1) inhibitors.
AID298724Cardioprotective effect against ischemia reperfusion injury in rat heart assessed as left ventricular end diastolic pressure at 10 uM2007Bioorganic & medicinal chemistry letters, Mar-01, Volume: 17, Issue:5
3-Substituted-(5-arylfuran-2-ylcarbonyl)guanidines as NHE-1 inhibitors.
AID701664Mean resident time in jugular and femoral vein precannulated Sprague-Dawley rat at 1 mg/kg, iv by LC/MS/MS analysis2012Journal of medicinal chemistry, Aug-23, Volume: 55, Issue:16
Identification of a potent sodium hydrogen exchanger isoform 1 (NHE1) inhibitor with a suitable profile for chronic dosing and demonstrated cardioprotective effects in a preclinical model of myocardial infarction in the rat.
AID358119Inhibition of human wild type NHE1 expressed in chinese hamster AP1 cells assessed as intracellular pHi recovery by ammonium chloride prepulse protocol2007The Journal of biological chemistry, Jul-06, Volume: 282, Issue:27
NHE1 inhibition by amiloride- and benzoylguanidine-type compounds. Inhibitor binding loci deduced from chimeras of NHE1 homologues with endogenous differences in inhibitor sensitivity.
AID295040Inhibition of NHE1 in rat platelets by Platelet swelling assay2007Bioorganic & medicinal chemistry letters, May-01, Volume: 17, Issue:9
Benzimidazol-2-yl or benzimidazol-2-ylthiomethyl benzoylguanidines as novel Na+/H+ exchanger inhibitors, synthesis and protection against ischemic-reperfusion injury.
AID143810Compound is screened in AP1 cells expressing human NHE-5 for sodium hydrogen exchange activity2001Journal of medicinal chemistry, Sep-27, Volume: 44, Issue:20
Arylcyclopropanecarboxyl guanidines as novel, potent, and selective inhibitors of the sodium hydrogen exchanger isoform-1.
AID701663Volume of distribution at steady state in jugular and femoral vein precannulated Sprague-Dawley rat at 1 mg/kg, iv by LC/MS/MS analysis2012Journal of medicinal chemistry, Aug-23, Volume: 55, Issue:16
Identification of a potent sodium hydrogen exchanger isoform 1 (NHE1) inhibitor with a suitable profile for chronic dosing and demonstrated cardioprotective effects in a preclinical model of myocardial infarction in the rat.
AID298722Inhibition of human NHE1 expressed in PS120 cells2007Bioorganic & medicinal chemistry letters, Mar-01, Volume: 17, Issue:5
3-Substituted-(5-arylfuran-2-ylcarbonyl)guanidines as NHE-1 inhibitors.
AID295038Cardioprotective effect against myocardial ischemic-reperfusion injury in Sprague-Dawley rat assessed as serum creatine kinase level at 0.01 mmol/kg, iv administered 5 mins before LAD occlusion2007Bioorganic & medicinal chemistry letters, May-01, Volume: 17, Issue:9
Benzimidazol-2-yl or benzimidazol-2-ylthiomethyl benzoylguanidines as novel Na+/H+ exchanger inhibitors, synthesis and protection against ischemic-reperfusion injury.
AID298723Cardioprotective effect against ischemia reperfusion injury in rat heart assessed as recovery of rate pressure product at 10 uM2007Bioorganic & medicinal chemistry letters, Mar-01, Volume: 17, Issue:5
3-Substituted-(5-arylfuran-2-ylcarbonyl)guanidines as NHE-1 inhibitors.
AID245757In vitro cardioprotective effect of compound on recovery of rate pressure product (RPP, HRxLVDP) to pre-ischemic value in rat heart; Control = 13%2005Bioorganic & medicinal chemistry letters, Jun-15, Volume: 15, Issue:12
4-Substituted (benzo[b]thiophene-2-carbonyl)guanidines as novel Na+/H+ exchanger isoform-1 (NHE-1) inhibitors.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (394)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's48 (12.18)18.2507
2000's260 (65.99)29.6817
2010's80 (20.30)24.3611
2020's6 (1.52)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 26.98

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index26.98 (24.57)
Research Supply Index6.04 (2.92)
Research Growth Index4.66 (4.65)
Search Engine Demand Index36.71 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (26.98)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials10 (2.44%)5.53%
Reviews30 (7.33%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other369 (90.22%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]